Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum

A proton pump inhibitor, duodenal ulcer technology, applied in the fields of medicine and pharmacy, can solve problems such as death, toxicity of antibiotics, dysbiosis of digestive tract, etc., and achieve the effect of promoting growth

Inactive Publication Date: 2012-01-25
亚历山大·弗拉基米罗维奇·季科夫斯基
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] The disadvantages of the above drugs are the toxic effects of antibacterial drugs and the dysbiosis of the digestive tract due to the inhibition of normal flora by antibacterial drugs
[0014] The disadvantages of the above drugs are the toxic effect of large doses of antibacterial drugs, and the lack of stable efficacy, because the heterologous strains of Lactobacillus and Bifidobacteria are excreted from the digestive tract by the new host within a few days, and the above-mentioned bacilli are stored in liquid dies quickly in culture

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum
  • Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum
  • Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024] The following introduces the clinical trial results of this pharmaceutical composition for the treatment of gastric ulcer and duodenal ulcer. As a specific embodiment of the present invention, the active ingredients of this pharmaceutical composition include: proton pump inhibitor (PPI) and prebiotics .

[0025] The detailed description demonstrates the synergistic effect of proton pump inhibitors and prebiotics (ie "stimulators" of the growth of the normal flora itself) in patients with gastric and duodenal ulcers.

[0026] The clinical trial was carried out on 80 newly diagnosed patients (male and female) aged from 19 to 57 with gastric and duodenal ulcers, 5 of whom had Zollinger-Ellison syndrome (Zollinger-Ellison syndrome).

[0027] All patients were divided into 8 groups with 10 people in each group. Among them, 4 groups were experimental groups, and patients took orally the above-mentioned dosage forms containing proton pump inhibitors and prebiotics. Group 1,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A pharmaceutical composition comprising proton pump inhibitors and prebiotics is proposed for the treatment of gastric and duodenal ulcer, this allowing effective ulcer treatment and eradication of H. pylori from the gastric and duodenal mucosa to be carried out without using wide-spectrum antibiotics. The comprehensive treatment of ulcer disease associated with a helicobaterial infection using a pharmaceutical composition of a PPI and a prebiotic makes it possible, in conditions of an elevated pH of the stomach contents, actively to stimulate the growth of lactobacilli in the upper sections of the gastrointestinal tract, including the duodenum, and substantially to increase the titre of lactobacilli, which are antagonists of H. pylori, which greatly improves the effectiveness of the ulcer treatment.; The high clinical effectiveness and safety resulting from the synergistic action of the proton pump inhibitor and the prebiotic in the upper sections of the gastrointestinal tract, the absence of side effects and recurrences, and also the level of compliance to the combined treatment provided by the claimed pharmaceutical composition indicate that the proposed formulation is a promising new means for the treatment of gastric and duodenal ulcer. Use of the claimed composition dramatically reduces the number of recurrences of the illness.

Description

technical field [0001] The invention relates to the fields of medicine and pharmacy, and more to a pharmaceutical composition for treating gastric ulcer and duodenal ulcer. Background technique [0002] Gastric ulcer and duodenal ulcer are chronic diseases that are prone to relapse, and the main feature is the formation of ulcers on the gastric and duodenal mucosa. Such diseases are the most common lesions of the organs of the digestive tract. According to epidemiological data, 8-10% of adults in the world suffer from ulcer disease. 1% of children suffer from this disease. Ulcer disease is most common in young and middle-aged people. The ratio of gastric ulcer to duodenal ulcer incidence is 1:4. Among them, young people mainly suffer from duodenal ulcers, while the rate of gastric ulcers among middle-aged and elderly people gradually increases. Men are more likely than women to develop duodenal ulcers. [0003] The discovery of the role of Helicobacter pylori in the de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7016A61K31/702A61K31/4439A61P1/04
CPCA61K31/733A61K31/715A61K31/702A61K31/732A61K31/7016A61K31/047A61K45/06A61K31/4439A61K31/7032A61P1/00A61P1/04A61P31/04A61K2300/00
Inventor 亚历山大·弗拉基米罗维奇·季科夫斯基奥列格·瓦连京诺维奇·多罗日科
Owner 亚历山大·弗拉基米罗维奇·季科夫斯基
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products